Panacea Index Logo

Command Palette

Search for a command to run...

Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1.

Diabetes care
July 1, 2011
Jaime Uribarri et al. (9 authors)
Journal ArticleRandomized Controlled TrialResearch Support, N.I.H., ExtramuralResearch Support, U.S. Gov't, Non-P.H.S.Human StudyMolecular StudyClinical
Study Details

Study Goal

The researchers aimed to determine whether dietary advanced glycation end products (AGEs) contribute to insulin resistance in type 2 diabetes and whether AGE restriction can improve insulin sensitivity by modulating AGER1 and SIRT1 pathways.

Results Summary

The study found that an AGE-restricted diet reduced insulin resistance, inflammatory markers, and oxidative stress in type 2 diabetic patients while restoring AGER1 and SIRT1 levels. AGE restriction also improved adiponectin levels and suppressed pro-inflammatory pathways in vitro.

Population

18 type 2 diabetic patients (age 61±4 years) and 18 healthy subjects (age 67±1.4 years).

Effective Dosage

Standard diet (>20 AGE Eq/day) vs. AGE-restricted diet (<10 AGE Eq/day).

Duration

4 months.

Interactions

None mentioned.

Extracted Claims (17)
InterventionDirectionEndpointPopulationDosageImpactClaim #
AGE-restricted diet
decrease
Insulin
AGE-restricted type 2 diabetic patients
-
decreased
#1
AGE-restricted diet
decrease
homeostasis model assessment
AGE-restricted type 2 diabetic patients
-
decreased
#2
AGE-restricted diet
decrease
leptin
AGE-restricted type 2 diabetic patients
-
decreased
#3
AGE-restricted diet
decrease
tumor necrosis factor-α
AGE-restricted type 2 diabetic patients
-
decreased
#4
AGE-restricted diet
decrease
nuclear factor-κB p65 acetylation
AGE-restricted type 2 diabetic patients
-
decreased
#5
AGE-restricted diet
decrease
serum AGEs
AGE-restricted type 2 diabetic patients
-
decreased
#6
AGE-restricted diet
decrease
8-isoprostanes
AGE-restricted type 2 diabetic patients
-
decreased
#7
AGE-restricted diet
increase
PMNC AGER1 mRNA levels
AGE-restricted type 2 diabetic patients
-
normalized
#8
AGE-restricted diet
increase
PMNC SIRT1 mRNA levels
AGE-restricted type 2 diabetic patients
-
normalized
#9
AGE-restricted diet
increase
PMNC AGER1 protein levels
AGE-restricted type 2 diabetic patients
-
normalized
#10
AGE-restricted diet
increase
PMNC SIRT1 protein levels
AGE-restricted type 2 diabetic patients
-
normalized
#11
AGE-restricted diet
increase
adiponectin
AGE-restricted type 2 diabetic patients
-
markedly increased
#12
AGEs
decrease
AGER1 levels
THP-1 cells
-
suppressed
#13
AGEs
decrease
SIRT-1 levels
THP-1 cells
-
suppressed
#14
AGEs
decrease
NAD+ levels
THP-1 cells
-
suppressed
#15
AGEs
decrease
suppressive effects on AGER1, SIRT-1, and NAD+ levels
AGER1-transduced (AGER1+) THP-1 cells
-
inhibited
#16
AGEs
increase
suppressive effects on AGER1, SIRT-1, and NAD+ levels
AGER1-silenced THP-1 cells
-
enhanced
#17
Abstract

OBJECTIVE: Increased oxidative stress (OS) and impaired anti-OS defenses are important in the development and persistence of insulin resistance (IR). Several anti-inflammatory and cell-protective mechanisms, including advanced glycation end product (AGE) receptor-1 (AGER1) and sirtuin (silent mating-type information regulation 2 homolog) 1 (SIRT1) are suppressed in diabetes. Because basal OS in type 2 diabetic patients is influenced by the consumption of AGEs, we examined whether AGE consumption also affects IR and whether AGER1 and SIRT1 are involved. RESEARCH DESIGN AND METHODS: The study randomly assigned 36 subjects, 18 type 2 diabetic patients (age 61±4 years) and 18 healthy subjects (age 67±1.4 years), to a standard diet (>20 AGE equivalents [Eq]/day) or an isocaloric AGE-restricted diet (<10 AGE Eq/day) for 4 months. Circulating metabolic and inflammatory markers were assessed. Expression and activities of AGER1 and SIRT1 were examined in patients' peripheral blood mononuclear cells (PMNC) and in AGE-stimulated, AGER1-transduced (AGER1+), or AGER1-silenced human monocyte-like THP-1 cells. RESULTS: Insulin and homeostasis model assessment, leptin, tumor necrosis factor-α and nuclear factor-κB p65 acetylation, serum AGEs, and 8-isoprostanes decreased in AGE-restricted type 2 diabetic patients, whereas PMNC AGER1 and SIRT1 mRNA, and protein levels normalized and adiponectin markedly increased. AGEs suppressed AGER1, SIRT-1, and NAD+ levels in THP-1 cells. These effects were inhibited in AGER1+ but were enhanced in AGER1-silenced cells. CONCLUSIONS: Food-derived pro-oxidant AGEs may contribute to IR in clinical type 2 diabetes and suppress protective mechanisms, AGER1 and SIRT1. AGE restriction may preserve native defenses and insulin sensitivity by maintaining lower basal OS.

Medical Subject Headings (MeSH)
AgedCells, CulturedDiabetes Mellitus, Type 2FemaleGlycation End Products, AdvancedHumansHypoglycemic AgentsInflammationInsulin ResistanceLeukocytes, MononuclearMaleMiddle AgedOxidative StressReceptor for Advanced Glycation End ProductsReceptors, ImmunologicSirtuin 1
Study Links
Quality Scores
SafetyNot Assessed
Efficacy85/10
Quality80/10
Citation Metrics
Total Citations251
Citations/Year17.9
Relative Citation Ratio7.97
NIH Percentile96.8%
Research Impact Scores
APT Score0.95
Weight Score1.59
Normalized Score0.70
Restriction of advanced glycation end products improves insu... | Panacea Index